Mission Therapeutics appoints Dr Colin Goddard to its board of directors
pharmafile | July 2, 2015 | Appointment | Research and Development | Colin Goddard, Mission Therapeutics, appointments
MISSION Therapeutics, a drug discovery and development company today has appointed Dr Colin Goddard, former chief executive of OSI Pharmaceuticals, to the company’s board of directors.
“We are privileged to have Dr Goddard join our board at this exciting phase of Mission growth and development”, comments Michael Moore, chairman of MISSION Therapeutics.
Dr Goddard joined OSI as a research scientist in 1989 and led the transformation of the technology platform services company into a profitable, fully integrated biopharma firm, becoming chief executive in 1998.
Goddard was pivotal in the registration and launch of OSI’s targeted therapeutic product, Tarceva (erlotinib) and also directed the company’s financing, corporate development and acquisition strategies, completing several major acquisitions and divestitures and raising over $1.5bn in capital.
Dr Goddard obtained his PhD in cancer pharmacology from the University of Aston in Birmingham, and worked at the US National Cancer Institute in Bethesda, Maryland, before joining OSI.
He currently serves as executive chairman of US based biotech companies Coferon and Merganser Biotech and as a director on the boards of Endocyte and PanOptica, he was formerly a director at Human Genome Sciences.
“Dr Goddard has more than 25 years of outstanding leadership experience in the US biopharmaceutical industry and will add a complementary strategic dimension to our board. We look forward to benefiting from his corporate vision, as we continue to transition our business into a clinical stage organisation.”
Dr Anker Lundemose, chief executive of MISSION Therapeutics added: “We are pleased to welcome Dr Goddard to MISSION Therapeutics. His experience and track record in clinical development will be invaluable as we look to develop new drugs that will significantly improve the management of cancer.”
Related Content
FDA approves Mission Therapeutics’ phase 2 clinical trial for acute kidney injury treatment
Mission Therapeutics has announced that the US Food and Drug Administration (FDA) has approved its …
Sanofi axes four major players from its executive committee
Sanofi has announced it will cull its executive committee under plans orchestrated by new Chief …
Dr Richard Torbett is named as the new Chief Executive of the ABPI
The Association of the British Pharmaceutical Industry (ABPI) has appointed Dr Richard Torbett as its …
